OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Oculis Holding AG
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 4, 2026
$7.32+0.03 (+0.41%)
Close on Oct 19, 2026
Ownership
Who owns Oculis's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| LSP 7 Management B.V. | 6,950,294 | 11.80% | 13G (passive) amendment | Mar 31, 2026 |
| LSP 7 Cooperatieve U.A. | 5,752,894 | 13.80% | 13G (passive) amendment | Dec 31, 2024 |
| BVCF IV GP, Ltd. | 2,191,810 | 5.05% | 13G (passive) amendment | Nov 27, 2024 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Riad Sherif Officer, CEO | Mar 9, 2026 | 25,000 | $660.00K | Mar 9, 2026 | Issuance of earnout shares of Oculis Holding AG |
| Ackermann Christina Director | Oct 9, 2025 | 7,460 | $148.23K | Oct 9, 2025 | Exercise of Stock Options |
| Riad Sherif Officer, CEO | Sep 23, 2025 | 25,000 | $442.50K | Sep 23, 2025 | Issuance of earnout shares of Oculis Holding AG |
| Riad Sherif Officer, CEO | Mar 14, 2025 | 25,000 | $466.50K | Mar 14, 2025 | Issuance of earnout shares of Oculis Holding AG |